Romanian Pharma Giant Biotehnos Falls Prey to Lamashtu Ransomware in Brazen Attack

When the digital alarms rang across Otopeni, Romania, few outside the cybersecurity underground noticed. But within hours, the shadowy Lamashtu ransomware group had broadcast their latest conquest: Biotehnos, a pillar of Romania’s pharmaceutical industry with three decades of research and innovation behind its name. As the cybercriminals added Biotehnos to their growing roster of victims, the incident sounded a stark warning for an industry increasingly targeted for both its sensitive data and critical public health role.

Fast Facts

• Biotehnos, founded in 1993, is a leading Romanian pharmaceutical company based near Bucharest.
• Lamashtu, a notorious ransomware group, publicly listed Biotehnos as a victim in June 2024.
• No evidence of cloud or SaaS infrastructure was detected in Biotehnos’ DNS records.
• Ransomware.live reported the incident but did not provide or distribute any stolen data.
• Biotehnos celebrated its 30th anniversary in 2023, marking decades of biomedical research.

Inside the Attack: What We Know

On the surface, Biotehnos operates like any established pharmaceutical firm: research labs, supply chains, and proprietary formulations. But beneath that, their digital infrastructure has now become a battleground. Lamashtu - an emerging name in the ransomware underworld - announced the successful breach via their leak site, a tactic used to pressure organizations into paying ransom demands by threatening public exposure or sale of stolen data.

Technical details remain scarce. DNS records for Biotehnos’ domain revealed no reliance on major cloud or SaaS providers, suggesting the company may host operations on-premises or via less common service providers. This can be a double-edged sword: while avoiding well-known attack vectors in the cloud, it may expose organizations to vulnerabilities in legacy systems or under-resourced IT teams.

Lamashtu’s modus operandi typically involves infiltrating networks through phishing or exploiting unpatched vulnerabilities, encrypting critical files, and then demanding payment - often in cryptocurrency. While the group released a screenshot as proof of access, no actual stolen data has been publicly distributed, in line with ransomware groups’ strategy of maximizing fear while minimizing exposure until negotiations conclude.

The pharmaceutical sector is a prized target: attackers can disrupt drug production, threaten research secrets, and endanger patient data. Biotehnos’ breach is yet another reminder that even companies outside the global spotlight are not immune. As healthcare and biotech firms digitize, their attack surface widens - making robust cybersecurity not just a technical necessity, but a public health imperative.

Reflections: A Sector on Notice

For Biotehnos, the immediate impact remains unclear - will operations be disrupted, data leaked, or ransoms paid? But for the wider pharmaceutical industry, the message rings out: cybercriminals are watching, probing for weaknesses, and ready to strike. As Lamashtu adds another trophy to its list, the call for vigilance, investment, and cross-sector collaboration in cybersecurity has never been more urgent.

WIKICROOK

• Ransomware: Ransomware is malicious software that encrypts or locks data, demanding payment from victims to restore access to their files or systems.
• DNS Records: DNS records are digital instructions that direct internet traffic to the right servers, ensuring websites and services are accessible and secure.
• SaaS (Software as a Service): SaaS (Software as a Service) delivers cloud-based software online, letting users access and manage apps without local installation or maintenance.
• Phishing: Phishing is a cybercrime where attackers send fake messages to trick users into revealing sensitive data or clicking malicious links.
• On: On-device processing means data is handled locally on your device, not sent to external servers, improving privacy and security.